©2024 Stanford Medicine
A Pilot Study Evaluating Oral Triamcinalone in Patients With Androgen Independent Prostate Cancer
Not Recruiting
Trial ID: NCT00186108
Purpose
The primary purpose of this study is to evaluate the ability of oral triamcinalone given
twice a day to patients with androgen independent prostate cancer to produce a sustained
biochemical response. Secondary goals are to describe the safety and tolerability at this
dose and schedule, to determine the time to sustained biochemical response, to determine the
duration of biochemical response, to determine the time to disease progression.
Official Title
A Pilot Study Evaluating Oral Triamcinalone in Patients With Androgen Independent Prostate Cancer
Stanford Investigator(s)
Sandy Srinivas
Professor of Medicine (Oncology) and, by courtesy, of Urology
Eligibility
Inclusion Criteria:
- 18 years of age and older
- Histologically documented adenocarcinoma of prostate
- Currently receiving LHRH agonists with castrate levels of testosterone or who have had
an orchiectomy
- Must have had a rise in PSA despite anti androgen withdrawal
- Exhibit 2 consecutive rise in PSA after the last hormonal manipulation
- Minimum PSA of greater than 5 KPS greater than 80%
- Normal cortisol level at entry
- Life expectancy greater than 6 months
- Provide written consent pursuant to regulatory requirements prior to initiation of
study procedure
Exclusion criteria:
- Younger than 18 years
- Patients without prostate cancer
Intervention(s):
drug: Oral Triamcinalone
Not Recruiting
Contact Information
Stanford University
School of Medicine
300 Pasteur Drive
Stanford,
CA
94305
Denise Haas
6507361252